Sort

Search

01/01/2026 Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)
López-Tarruella, S, Guerrero-Zotano, A, Antolín, S, Cruz, J, Martínez, P, Rodríguez, CA, Falo, C, Rodríguez-Lescure, A, Adrover, E, Hernández, M, Andrés, R, Chacón, JI, Romero, JLA, Miguel, A, Gómez-Raposo, C, Margelí, M, González, I, Guerra, JA, Antón, A, Tibau, A, Miralles, JJ, Escudero, MJ, Bezares, S, Rojo, F, Alvarez, I. Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM). Therapeutic Advances in Medical Oncology. 2026; 18DOI:10.1177/17588359261421813. PMID:41732657. IF:4.200(Q2/3D).
01/01/2026 Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
Capdevila, J, Paez, D, Villacampa, MM, Garcia-Alvarez, A, Aparicio, J, Pampols, M, Riesco-Martinez, MD, Polo, E, Ruiz-Casado, A, Castañon, C, Soriano, S, Hernando, J, Navalpotro, B, Armario, D, Villacampa, G, Horvath, E, Virgili, AC, Asiain, L, Giménez, A, Guillot, M. Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.11. PMID:. IF:41.900(Q1/1D).
01/01/2026 A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.
Hayes, M, Nakajima, TE, Seecof, O, Majem, M, Chenji, S, Ashki, N, Ceccarelli, M, Van Cutsem, E. A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.TPS855. PMID:. IF:41.900(Q1/1D).
01/01/2026 Isocitrate dehydrogenase 1 mutations in biliary tract cancer patients in Spanish RETUD registry
Martín, AJM, Castet, F, Vera, R, Alvarez, R, Garcia-Alfonso, P, Alsar, JS, Palao, P, Diaz, IA, Vidal-Tocino, R, Adeva, J, Modrego, A, Maseda, AC, Martínez-Galán, J, Serda, PC, Rodriguez-Alonso, RM, Aranda, E, La Casta, A, de Castro, EM, Montes, AFF, Macarulla, T. Isocitrate dehydrogenase 1 mutations in biliary tract cancer patients in Spanish RETUD registry. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.500. PMID:. IF:41.900(Q1/1D).